Oral contrast for abdominal and pelvic CT: Difference between revisions

(Text replacement - "* " to "*")
(Text replacement - "abscess " to "abscess ")
Line 98: Line 98:
===Consider===
===Consider===
*Suspected low-grade [[bowel obstruction]]
*Suspected low-grade [[bowel obstruction]]
*Intra-abdominal abscess depending on the suspected primary source
*Intra-abdominal [[abscess]] depending on the suspected primary source
**May not be required if primary source is skin infection
**May not be required if primary source is skin infection
*Metastatic evaluation
*Metastatic evaluation

Revision as of 09:18, 10 March 2017

Background

  • For patients undergoing CT of abdomen and/or pelvis
  • Requires significant "lead time" - i.e. must administer >1hr prior to CT scan

Redypaque Dose

Weight

Give 1 hour prior to scan

Give 30 minutes prior to scan

Give immediately upon arrival to CT

< 2 kg

None or as ordered by physician

None or as ordered by physician

None or as ordered by physician

2-5 kg

30 mL

30 mL

30 mL

>5-20 kg

90 mL

90 mL

90 mL

>20-50 kg

150 mL

150 mL

150 mL

>50 kg

300 mL

300 mL

300 mL

(100cc/age)/3 = dose x 3

Max = 300cc

Indications

Desirable

Consider

  • Suspected low-grade bowel obstruction
  • Intra-abdominal abscess depending on the suspected primary source
    • May not be required if primary source is skin infection
  • Metastatic evaluation
  • Suspected Hernia

Not Indicated

  • Emergent process needing immediate CT
  • Delays in time to imaging due to prolonged intolerance of oral contrast
  • Uncomplicated Appendicitis or Diverticulitis with BMI >20
  • Suspected high-grade or severe bowel obstruction
  • Suspected aneurysm, dissection, or vessel thrombosis
  • Suspected bowel ischemia or infarct
  • Nephrolithiasis protocol
  • Pancreatic protocol for Pancreatitis or mass
  • Liver protocol for liver mass or abscess
  • Adrenal protocol for adrenal mass or nodules
  • Superficial abdominal wall infections or abscesses
  • Inflammatory bowel disease

See Also

References